drugset / Trial / NCT05745467

Povidone Iodine Nasal Application to Prevent Intraoperative Spread of SARS-CoV-2

NCT05745467 ↗

Phase 4 Withdrawn University of Iowa 3M · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

The primary aim is to test whether preoperative asepsis with 5% nasal povidone iodine versus no preoperative asepsis with 5% nasal povidone iodine reduces proximal and distal SARS-CoV-2 transmission in operating rooms among patients who are acutely infected with SARS-CoV-2. The secondary aim is to test viral infectivity.

Timeline

Start
2024-07-03
Primary completion
2025-07-01
Completion
2026-04-01

Outcome

Outcome not reported

Stopped: “Wouldn't be able to get enough patients. Never started the study. Suspended the IRB form.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Povidone-Iodine Other / unclassified 5 % —

Indications